公开(公告)号：US20250082869A1

公开(公告)日：2025-03-13

申请号：US18726062

申请日：2022-11-07

Applicant: CANSINO BIOLOGICS INC. ,  STAMFORD DEVICES LIMITED

Inventor： Weixue SI ,  Xiaolong ZHAO ,  Yueran WANG ,  Yueying JIANG ,  Liping WANG ,  Xuefeng YU ,  Shoubai CHAO ,  Tao ZHU

IPC: A61M11/00

Abstract: Disclosed are a nebulization cup and application in nebulized inhalation administration thereof, and especially application in nebulized inhalation administration of a preventive and/or therapeutic drug for a respiratory disease (such as SARS-CoV-2 vaccine). After adding an antistatic agent, the nebulization cup can effectively maintain the stability of drug mist within a certain period of time, with stable particle size, less drug residue in the cup, thus ensuring effective inhalable amount, and the administration operation is simple and convenient, thus the nebulization cup can significantly improve the inoculation efficiency and can be used for large-scale inoculation.

公开(公告)号：US20230111095A1

公开(公告)日：2023-04-13

申请号：US17769607

申请日：2020-09-25

Applicant: Cansino Biologics Inc.

Inventor： Haomeng WANG ,  Qiaoling YAN ,  Shoubai CHAO ,  Huhua MAO ,  Tao ZHU

IPC: A61K39/385 ,  A61P31/04 ,  A61K39/09

Abstract: The present invention relates to a carrier protein with site-directed mutation and use thereof in preparation of a vaccine, wherein the carrier protein is selected from fusion proteins formed by one, two or more of diphtheria toxoid, a non-toxic mutant of diphtheria toxin, a bacterial outer membrane protein and a bacterially expressed protein, wherein an amino acid at at least one site on the carrier protein is mutated into an unnatural amino acid, and the unnatural amino acid contains an azido or alkynyl terminal group. In a mutual reaction process of the carrier protein with site-directed mutation of the present invention and a polysaccharide antigen, a covalent bond is formed, and meanwhile a formed conjugate is in a bead-string state, so that the carrier protein and the polysaccharide antigen can be effectively prevented from being excessively crosslinked. Further, particle size distribution of the conjugate is significantly uniform and controllable, which provides an effective means for improving quality of a polysaccharide-protein conjugate vaccine.

公开(公告)号：US10716847B2

公开(公告)日：2020-07-21

申请号：US15940871

申请日：2018-03-29

Applicant: CANSINO BIOLOGICS INC.

Inventor： Junqiang Li ,  Danqing Miao ,  Mingming Yang ,  Zhongqi Shao ,  Tao Zhu ,  Xuefeng Yu

IPC: A61K39/02 ,  A61K39/385 ,  A61K39/102 ,  C07K19/00 ,  C12N15/62 ,  A61K47/64 ,  A61K39/00

Abstract: Provided are a fusion protein and a construction method thereof. The fusion method consists of: a Haemophilus influenzae protein D and a Hin47 (Htra) protein. The fusion protein can serve as a protein vehicle for a Haemophilus influenzae polysaccharide-protein conjugate vaccine, thereby increasing immunogenicity of a polysaccharide antigen.

公开(公告)号：US11795475B2

公开(公告)日：2023-10-24

申请号：US16806013

申请日：2020-03-02

Applicant: CANSINO BIOLOGICS INC.

Inventor： Tao Zhu ,  Haiyan Cui ,  Weiwei Chen ,  Lei Duan ,  Junqiang Li ,  Jin Ma ,  Chunlin Xin ,  Zhongqi Shao ,  Xuefeng Yu ,  Huihua Mao

IPC: C12N15/86 ,  A61K39/235 ,  C12N5/071

CPC classification number: C12N15/86 ,  A61K39/235 ,  C12N5/0686

Abstract: Provided are a cell strain HEK293.CS for reducing the production of a replication competent adenovirus, and a construction method and the use thereof. HEK293.CS is a safe adenovirus-producing cell line constructed by knocking out a gene fragment homologous to the Ad5 adenovirus E1 gene in HEK293 and providing a template plasmid to replace said gene fragment with a non-homologous sequence that stabilizes the expression of the E1 gene. Compared with the unmodified HEK293 cell strain, HEK293.CS shows no decrease in growth ability and virus production ability, but does not produce a detectable RCA. HEK293.CS can be used for the mass culture of a recombinant human type 5 adenovirus, and reducing the probability of RCA production in the manufacture process of drugs such as vaccines and antibodies.

公开(公告)号：US10125175B2

公开(公告)日：2018-11-13

申请号：US15438790

申请日：2017-02-22

Applicant: CANSINO BIOLOGICS INC.

Inventor： Zhongqi Shao ,  Junqiang Li ,  Rong Jiang ,  Mingming Yang ,  Tao Zhu ,  Helen Huihua Mao ,  Xuefeng Yu

IPC: C07K14/025 ,  A61K39/29 ,  C12N15/66 ,  A61K39/12 ,  C12N7/04 ,  A61K39/00

Abstract: A method for enhancing immunogenicity of an epitope peptide of an HPV antigen, the method including: assembling a gene of an HPV antigen into a gene of HBc, exogenously expressing a resulting assembled gene to acquire a fusion protein, allowing the fusion protein to automatically assemble to form a virus-like particle including the HPV antigen on a surface of the virus-like particle, to obtain HBc-HPV virus-like particle. A virus-like particle capable of expressing the antigen peptide of HPV acquired by the method. The virus-like particle includes a HBc-L2 fusion protein. A genome for encoding the HBc-L2 fusion protein is represented by SEQ ID NO. 3. A method for preparing an HPV vaccine includes using the virus-like particle.

公开(公告)号：US20230313225A1

公开(公告)日：2023-10-05

申请号：US18011742

申请日：2021-11-08

Applicant: CANSINO BIOLOGICS INC.

Inventor： Meng XIAO ,  Yunjie LIU ,  Tao ZHU ,  Yunli XU ,  Can XU ,  Junqiang LI ,  Shoubai CHAO

IPC: C12N15/86 ,  C12M1/00 ,  A61K39/215

CPC classification number: C12N15/86 ,  C12M29/10 ,  A61K39/215 ,  C12N2710/10334 ,  C12N2710/10343 ,  C12N2710/10352 ,  C12N2710/10362 ,  C12N2500/32 ,  A61K2039/5256

Abstract: Provided is a method for preparing an adenovirus vector vaccine by means of a perfusion culture process. The method comprises a step of culturing adenovirus host cells, and in particular a step of adjusting the perfusion rate by means of at least two stages according to cell density. The method increases the single cell yield of a virus after infection and the specific activity of a virus harvest liquid while achieving high-density growth of adenovirus host cells.

公开(公告)号：US20230022109A1

公开(公告)日：2023-01-26

申请号：US17606792

申请日：2020-06-15

Applicant: ACADEMY OF MILITARY MEDICAL SCIENCE, PLA ,  CANSINO BIOLOGICS INC.

Inventor： Wei Chen ,  Shipo Wu ,  Lihua Hou ,  Zhe Zhang ,  Busen Wang ,  Qiang Guo ,  Jinlong Zhang ,  Xiaohong Song ,  Ling Fu ,  Jun Zhang ,  Yi Chen ,  Zhenghao Zhao ,  Tao Zhu ,  Jin Li ,  Chunlin Xin

IPC: A61K39/215 ,  A61P31/14 ,  C12N15/86 ,  C07K14/005

Abstract: Provided is a novel coronavirus vaccine using replication-deficient human type 5 adenovirus as a vector. The vaccine takes the replication-deficient human type 5 adenovirus that is lack of E1 and E3 in a combined mode as a vector, and HEK293 cells that integrate adenovirus E1 genes serve as a packaging cell line, and protective antigenic genes carried are optimized COVID-19 (SARS-CoV-2) S protein genes (Ad5-nCoV). The vaccine has good immunogenicity in both mouse and guinea pig models and can induce the body to produce a strong cellular and humoral immune responses in a short time. Research on the protective effect of hACE2 transgenic mice shows that 14 days after a single Ad5-nCoV immunization, the viral load in lung tissues can be significantly reduced. It shows that the vaccine has a good immune protection effect against COVID-19.

公开(公告)号：US20200255862A1

公开(公告)日：2020-08-13

申请号：US16806013

申请日：2020-03-02

Applicant: CANSINO BIOLOGICS INC.

Inventor： Tao ZHU ,  Haiyan CUI ,  Weiwei CHEN ,  Lei DUAN ,  Junqiang LI ,  Jin MA ,  Chunlin XIN ,  Zhongqi SHAO ,  Xuefeng YU ,  Huihua MAO

IPC: C12N15/86 ,  A61K39/235

Abstract: Provided are a cell strain HEK293.CS for reducing the production of a replication competent adenovirus, and a construction method and the use thereof. HEK293.CS is a safe adenovirus-producing cell line constructed by knocking out a gene fragment homologous to the Ad5 adenovirus E1 gene in HEK293 and providing a template plasmid to replace said gene fragment with a non-homologous sequence that stabilizes the expression of the E1 gene. Compared with the unmodified HEK293 cell strain, HEK293.CS shows no decrease in growth ability and virus production ability, but does not produce a detectable RCA. HEK293.CS can be used for the mass culture of a recombinant human type 5 adenovirus, and reducing the probability of RCA production in the manufacture process of drugs such as vaccines and antibodies.

公开(公告)号：US20230183298A1

公开(公告)日：2023-06-15

申请号：US18150496

申请日：2023-01-05

Applicant: CANSINO BIOLOGICS INC.

Inventor： Haomeng WANG ,  Zhihong YAN ,  Qiaoling YAN ,  Juan SHAO ,  Jianming SHI ,  Xiuwen SUI ,  Junqiang LI ,  Tao ZHU

IPC: C07K14/22 ,  A61K39/116

CPC classification number: C07K14/22 ,  A61K39/116

Abstract: Provided are a protein antigen subjected to site-directed mutation and site-directed modification, and a method for site-directed mutation and site-directed modification of the protein antigen. The method comprises: site-directedly introducing an unnatural amino acid into a specific site of the protein antigen by genetic codon expansion technique; and performing site-directed modification with the protein antigen by the unnatural amino acid and a modifier, wherein the modifier is a receptor agonist such as tripalmitoyl-S-glyceryl cysteine and monophosphoryl lipid A. Further provided is use of the protein antigen subjected to site-directed mutation and site-directed modification, such as use as a vaccine.

公开(公告)号：US20230173058A1

公开(公告)日：2023-06-08

申请号：US17922328

申请日：2021-04-01

Applicant: CANSINO BIOLOGICS INC. ,  ACADEMY OF MILITARY MEDICAL SCIENCES, PLA

Inventor： Junqiang LI ,  Weixue SI ,  Tao ZHU ,  Yunli XU ,  Jie DENG ,  Shoubai CHAO

IPC: A61K39/215 ,  A61K47/42 ,  A61K47/26 ,  A61P31/14

CPC classification number: A61K39/215 ,  A61K47/42 ,  A61K47/26 ,  A61P31/14 ,  A61K2039/5256

Abstract: Disclosed is a SARS-CoV-2 vaccine, wherein the S protein of SARS-CoV-2 serves as the antigen, and the vaccine comprises an adenoviral vector, and the vaccine induces an improved protective immune response through mucosal immunity, thus preventing SARS-CoV-2 infection. Specifically, when atomized by an appropriate apparatus, the vaccine generates particles of improved uniformity, which can reach the lungs after being inhaled via the nasal cavity or the oral cavity, thus producing a protective immune response with respect to the entire respiratory tract and the lungs, enhancing the effective utilization rate of the vaccine, and increasing the effect of the vaccine.